Press releases

Zelenkofske to lead development and implementation of pre- and post-market clinical strategy that supports Company's CRM technology and therapy portfolio

Positive results also reported for TAXUS Liberte stent direct stenting

Results were announced at the Cardiovascular Research Foundation's (CRF) eighteenth annual Transcatheter Cardiovascular Therapeutics (TCT) scientific symposium, in Washington, D.C.

Results also show statistically significant late stent thrombosis rate for Cypher® stent vs. bare-metal stent

Two-year results continue to evaluate long-term safety and efficacy

Multi-center registry to enroll 10,000 patients over two years

Study of 1,558 patients was designed to retrospectively compare one-year clinical outcomes in real-world practice

"In Q3 we were able to achieve results near the high end of our previously announced preliminary sales and earnings ranges," said Jim Tobin, President and CEO

Results to include new data on next-generation TAXUS® Liberte™ Stent System

MAPS trial demonstrates Company's commitment to understanding the efficacy and durability of endovascular therapies for the treatment of brain aneurysms

Boston Scientific Corporation (NYSE: BSX) announced today that the PROMUS™ Everolimus-Eluting Coronary Stent System has received CE Mark...

Victory supports previous court decisions related to the suit Medtronic filed against Guidant in August 2003

A live webcast and replay of the October 18 conference call will be available

FDA approval makes remote monitoring available by more than 150,000 additional patients

Gobierno de Puerto Rico aprueba el Sistema Precision, que brinda a los médicos una nueva opción de tratamiento para dolor agudo y crónico

Plans for changes consistent with HRS guidelines includes Company's commitment to the development of independent, industry-wide oversight to facilitate consistent communications, surveillance and product performance reporting practices

New cochlear implant technology to significantly increase hearing potential and quality of life for the severe-to-profoundly deaf.

CryoPlasty® Therapy may be an alternative to surgery or limb amputation

“We made progress on a number of fronts, most notably the integration of Guidant and our quality initiatives," said Jim Tobin, President and CEO.

FLEXView™ System enables physicians to perform less-invasive cardiac surgical ablation procedures

Company welcomes FDA statement that drug-eluting stents remain safe and effective when used for approved indications

NEJM editorial and articles describe results of two randomized clinical trials, PASSION and TYPHOON

Boston Scientific Corporation (NYSE: BSX) today announced four-year follow-up data from its TAXUS II paclitaxel-eluting stent system...

Initial six-month results show positive outcomes in diabetic patients; safety events for diabetic subset lower than overall patient population

International data suggests low revascularization rates for both TAXUS stent and PROMUS™ (XIENCE™ V) stent